Stem Cell Therapy and Administration Routes After Stroke

Overview

Journal Transl Stroke Res

Publisher Springer

Date 2016 Jul 8

PMID 27384771

Citations 56

Authors

Berta Rodriguez-Frutos

Laura Otero-Ortega

Maria Gutierrez-Fernandez

Blanca Fuentes

Jaime Ramos-Cejudo

Exuperio Diez-Tejedor

Affiliations

Soon will be listed here.

Abstract

Cell-based therapy has demonstrated safety and efficacy in experimental animal models of stroke, as well as safety in stroke patients. However, various questions remain regarding the therapeutic window, dosage, route of administration, and the most appropriate cell type and source, as well as mechanisms of action and immune-modulation to optimize treatment based on stem cell therapy. Various delivery routes have been used in experimental stroke models, including intracerebral, intraventricular, subarachnoid, intra-arterial, intraperitoneal, intravenous, and intranasal routes. From a clinical point of view, it is necessary to demonstrate which is the most feasible, safest, and most effective for use with stroke patients. Therefore, further experimental studies concerning the safety, efficacy, and mechanisms of action involved in these therapeutic effects are required to determine their optimal clinical use.

Citing Articles

Critical criteria for improvising the efficacy of transplanted cells; Significance of route of administration and microenvironment at the target site.

J Stem Cells Regen Med. 2025; 20(2):24-25.

PMID: 39850637 PMC: 11750065. DOI: 10.46582/jsrm.2002004.

Research progress and challenges of stem cell therapy for ischemic stroke.

Cha Z, Qiao Y, Lu Q, Wang Q, Lu X, Zhou H Front Cell Dev Biol. 2024; 12:1410732.

PMID: 39040041 PMC: 11260720. DOI: 10.3389/fcell.2024.1410732.

Probing Multiple Transplant Delivery Routes of CD+34 Stem Cells for Promoting Behavioral and Histological Benefits in Experimental Ischemic Stroke.

Lee J, Cho J, DEgidio F, Vignon C, Streefkerk H, de Kalbermatten M Stem Cells Transl Med. 2023; 13(2):177-190.

PMID: 38016184 PMC: 10872715. DOI: 10.1093/stcltm/szad081.

Hypoxia and interleukin-1-primed mesenchymal stem/stromal cells as novel therapy for stroke.

Salaudeen M, Allan S, Pinteaux E Hum Cell. 2023; 37(1):154-166.

PMID: 37987924 PMC: 10764391. DOI: 10.1007/s13577-023-00997-1.

Comparison of the Administration Route of Stem Cell Therapy for Ischemic Stroke: A Systematic Review and Meta-Analysis of the Clinical Outcomes and Safety.

Fauzi A, Thamrin A, Permana A, Ranuh I, Hidayati H, Hamdan M J Clin Med. 2023; 12(7).

PMID: 37048818 PMC: 10094955. DOI: 10.3390/jcm12072735.

References

Leu S, Lin Y, Yuen C, Yen C, Kao Y, Sun C . Adipose-derived mesenchymal stem cells markedly attenuate brain infarct size and improve neurological function in rats. J Transl Med. 2010; 8:63. PMC: 2913939. DOI: 10.1186/1479-5876-8-63. View

Cui L, Kerkela E, Bakreen A, Nitzsche F, Andrzejewska A, Nowakowski A . The cerebral embolism evoked by intra-arterial delivery of allogeneic bone marrow mesenchymal stem cells in rats is related to cell dose and infusion velocity. Stem Cell Res Ther. 2015; 6:11. PMC: 4429328. DOI: 10.1186/scrt544. View

Rabinovich S, Seledtsov V, Banul N, Poveshchenko O, Senyukov V, Astrakov S . Cell therapy of brain stroke. Bull Exp Biol Med. 2005; 139(1):126-8. DOI: 10.1007/s10517-005-0229-y. View

Ohshima M, Taguchi A, Tsuda H, Sato Y, Yamahara K, Harada-Shiba M . Intraperitoneal and intravenous deliveries are not comparable in terms of drug efficacy and cell distribution in neonatal mice with hypoxia-ischemia. Brain Dev. 2014; 37(4):376-86. DOI: 10.1016/j.braindev.2014.06.010. View

Sun J, Wei Z, Gu X, Zhang J, Zhang Y, Li J . Intranasal delivery of hypoxia-preconditioned bone marrow-derived mesenchymal stem cells enhanced regenerative effects after intracerebral hemorrhagic stroke in mice. Exp Neurol. 2015; 272:78-87. DOI: 10.1016/j.expneurol.2015.03.011. View

Savitz S, Misra V, Kasam M, Juneja H, Cox Jr C, Alderman S . Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011; 70(1):59-69. DOI: 10.1002/ana.22458. View

Cui L, Qu H, Xiao T, Zhao M, Jolkkonen J, Zhao C . Stromal cell-derived factor-1 and its receptor CXCR4 in adult neurogenesis after cerebral ischemia. Restor Neurol Neurosci. 2013; 31(3):239-51. DOI: 10.3233/RNN-120271. View

Otero L, Zurita M, Bonilla C, Aguayo C, Vela A, Rico M . Late transplantation of allogeneic bone marrow stromal cells improves neurologic deficits subsequent to intracerebral hemorrhage. Cytotherapy. 2011; 13(5):562-71. DOI: 10.3109/14653249.2010.544720. View

Darsalia V, Kallur T, Kokaia Z . Survival, migration and neuronal differentiation of human fetal striatal and cortical neural stem cells grafted in stroke-damaged rat striatum. Eur J Neurosci. 2007; 26(3):605-14. DOI: 10.1111/j.1460-9568.2007.05702.x. View

10.

Wei Z, Gu X, Ferdinand A, Lee J, Ji X, Ji X . Intranasal delivery of bone marrow mesenchymal stem cells improved neurovascular regeneration and rescued neuropsychiatric deficits after neonatal stroke in rats. Cell Transplant. 2015; 24(3):391-402. DOI: 10.3727/096368915X686887. View

11.

Balseanu A, Buga A, Catalin B, Wagner D, Boltze J, Zagrean A . Multimodal Approaches for Regenerative Stroke Therapies: Combination of Granulocyte Colony-Stimulating Factor with Bone Marrow Mesenchymal Stem Cells is Not Superior to G-CSF Alone. Front Aging Neurosci. 2014; 6:130. PMC: 4066299. DOI: 10.3389/fnagi.2014.00130. View

12.

van Velthoven C, Sheldon R, Kavelaars A, Derugin N, Vexler Z, Willemen H . Mesenchymal stem cell transplantation attenuates brain injury after neonatal stroke. Stroke. 2013; 44(5):1426-32. PMC: 3694433. DOI: 10.1161/STROKEAHA.111.000326. View

13.

Battistella V, de Freitas G, Barbosa da Fonseca L, Mercante D, Gutfilen B, Goldenberg R . Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke. Regen Med. 2010; 6(1):45-52. DOI: 10.2217/rme.10.97. View

14.

Taguchi A, Sakai C, Soma T, Kasahara Y, Stern D, Kajimoto K . Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke: Phase1/2a Clinical Trial in a Homogeneous Group of Stroke Patients. Stem Cells Dev. 2015; 24(19):2207-18. PMC: 4582686. DOI: 10.1089/scd.2015.0160. View

15.

Liu X, Ye R, Yan T, Yu S, Wei L, Xu G . Cell based therapies for ischemic stroke: from basic science to bedside. Prog Neurobiol. 2013; 115:92-115. PMC: 4038267. DOI: 10.1016/j.pneurobio.2013.11.007. View

16.

Otero L, Zurita M, Bonilla C, Aguayo C, Rico M, Rodriguez A . Allogeneic bone marrow stromal cell transplantation after cerebral hemorrhage achieves cell transdifferentiation and modulates endogenous neurogenesis. Cytotherapy. 2011; 14(1):34-44. DOI: 10.3109/14653249.2011.608349. View

17.

Buhnemann C, Scholz A, Bernreuther C, Malik C, Braun H, Schachner M . Neuronal differentiation of transplanted embryonic stem cell-derived precursors in stroke lesions of adult rats. Brain. 2006; 129(Pt 12):3238-48. DOI: 10.1093/brain/awl261. View

18.

Moniche F, Gonzalez A, Gonzalez-Marcos J, Carmona M, Pinero P, Espigado I . Intra-arterial bone marrow mononuclear cells in ischemic stroke: a pilot clinical trial. Stroke. 2012; 43(8):2242-4. DOI: 10.1161/STROKEAHA.112.659409. View

19.

Li Y, Chen J, Wang L, Lu M, Chopp M . Treatment of stroke in rat with intracarotid administration of marrow stromal cells. Neurology. 2001; 56(12):1666-72. DOI: 10.1212/wnl.56.12.1666. View

20.

Friedrich M, Martins M, Araujo M, Klamt C, Vedolin L, Garicochea B . Intra-arterial infusion of autologous bone marrow mononuclear cells in patients with moderate to severe middle cerebral artery acute ischemic stroke. Cell Transplant. 2012; 21 Suppl 1:S13-21. DOI: 10.3727/096368912x612512. View